source
- Induced pluripotent stem cells gain momentum as new methods and clinical successes drive drug developmentInduced pluripotent stem cells (iPSCs) are moving from a research curiosity to a practical tool in drug development. After years of steady progress, recent advances are bringing iPSCs into the spot…
- Nouscom secures €120M to advance off-the-shelf cancer vaccine for Lynch syndromeSwiss biotech Nouscom announced a €120 million (about $135 million) Series D financing round. The capital will fund a registration-enabling pivotal trial of its cancer-preventing vaccine candidate.…